However, the predictive value of hormone receptor expression in endometrial cancer is not as strong as it is for patients with breast cancer due to the limitations associated with a lack of standardisation of tissue processing and factors such as a well-defined cut-off limit in relation to receptor levels.20 This evidence concerns the gene NR4A1 and breast cancer.